Defining and classifying terminology for medication harm: a call for consensus.


Journal

European journal of clinical pharmacology
ISSN: 1432-1041
Titre abrégé: Eur J Clin Pharmacol
Pays: Germany
ID NLM: 1256165

Informations de publication

Date de publication:
Feb 2019
Historique:
received: 23 07 2018
accepted: 25 09 2018
pubmed: 13 10 2018
medline: 10 5 2019
entrez: 13 10 2018
Statut: ppublish

Résumé

The multiplicity in terms and definitions of medication-related harm has been a long-standing challenge for health researchers, clinicians, and regulatory bodies. The purpose of this narrative review was to report the diversity of terms; compare definitions, classifications, and models describing medication harm; and suggest which may be useful in both clinical practice and the research setting. A narrative review of key studies defining and/or classifying medication harm terminology was undertaken. This review found that numerous terms are used to describe medication harm, and that there is a lack of consistency in current definitions, classifications, and applications. This lack of consistency applied across clinical jurisdictions and regulatory terminologies. A number of limitations in current definitions and classifications were identified. These included the exclusion of key types of medication harm events, ambiguous wording, and a lack of clarity and consensus on subclassifications. In general, there was some overlap in key models from the literature and these were presented to describe similarities and differences. Without uniformity quantifying, comparing, combining, or extrapolating medication harm data, such as a rate of harm in a specific population, is a challenge for those involved in medication safety and pharmacovigilance. There is a pressing need for further discussion and international consensus on this topic. Adoption of standard descriptors by practitioner groups, regulatory and policy organisations would foster quality improvement and patient safety.

Identifiants

pubmed: 30310967
doi: 10.1007/s00228-018-2567-5
pii: 10.1007/s00228-018-2567-5
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

137-145

Références

Drug Saf. 2000 Jun;22(6):415-23
pubmed: 10877036
Lancet. 2000 Oct 7;356(9237):1255-9
pubmed: 11072960
BMJ. 2003 Nov 22;327(7425):1222-5
pubmed: 14630763
Ann Intern Med. 2004 May 18;140(10):795-801
pubmed: 15148066
BMJ. 2004 Jul 3;329(7456):15-9
pubmed: 15231615
Qual Saf Health Care. 2004 Aug;13(4):306-14
pubmed: 15289635
Ann Intern Med. 2005 Jan 4;142(1):77; author reply 77-8
pubmed: 15630112
Drug Saf. 2005;28(10):851-70
pubmed: 16180936
Qual Saf Health Care. 2005 Oct;14(5):358-63
pubmed: 16195570
Qual Saf Health Care. 2006 Feb;15(1):39-43
pubmed: 16456208
Res Social Adm Pharm. 2006 Jun;2(2):280-9
pubmed: 17138513
N Engl J Med. 1991 Feb 7;324(6):377-84
pubmed: 1824793
PLoS One. 2009;4(2):e4439
pubmed: 19209224
Br J Clin Pharmacol. 2009 Jun;67(6):599-604
pubmed: 19594526
Drug Saf. 2010 Nov 1;33(11):995-1002
pubmed: 20925437
Int J Qual Health Care. 2010 Dec;22(6):507-18
pubmed: 20956285
N Engl J Med. 2011 Nov 24;365(21):2002-12
pubmed: 22111719
DICP. 1990 Nov;24(11):1093-7
pubmed: 2275235
Am J Hosp Pharm. 1990 Mar;47(3):533-43
pubmed: 2316538
J Intern Med. 1990 Aug;228(2):83-90
pubmed: 2394974
Br J Clin Pharmacol. 2013 Sep;76 Suppl 1:56-68
pubmed: 24007453
J Am Med Inform Assoc. 2014 May-Jun;21(3):547-57
pubmed: 24222671
Implement Sci. 2015 Aug 07;10:110
pubmed: 26250159
Br J Clin Pharmacol. 2017 Feb;83(2):416-426
pubmed: 27614089
Br J Clin Pharmacol. 2018 May;84(5):846-864
pubmed: 29337387
Clin Pharmacol Ther. 1981 Aug;30(2):239-45
pubmed: 7249508
J Gen Intern Med. 1995 Apr;10(4):199-205
pubmed: 7790981
JAMA. 1995 Jul 5;274(1):29-34
pubmed: 7791255
Am J Health Syst Pharm. 1998 Jan 15;55(2):165-6
pubmed: 9465983
JAMA. 1998 Apr 15;279(15):1200-5
pubmed: 9555760

Auteurs

Nazanin Falconer (N)

School of Pharmacy, Pharmacy Australia Centre of Excellence, The University of Queensland, 20 Cornwall Street, Woolloongabba, Brisbane, QLD, 4102, Australia. n.falconer@uq.net.au.

Michael Barras (M)

School of Pharmacy, Pharmacy Australia Centre of Excellence, The University of Queensland, 20 Cornwall Street, Woolloongabba, Brisbane, QLD, 4102, Australia.
Princess Alexandra Hospital, Metro South Health, Brisbane, QLD, 4102, Australia.

Jennifer Martin (J)

School of Medicine and Public Health, The University of New Castle, University Dr, Callaghan, NSW, 2308, Australia.
The Hunter Medical Research Institute, New Lambton, NSW, 2305, Australia.

Neil Cottrell (N)

School of Pharmacy, Pharmacy Australia Centre of Excellence, The University of Queensland, 20 Cornwall Street, Woolloongabba, Brisbane, QLD, 4102, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH